Allarity Therapeutics Inc (ALLR) FinancialsALLRAllarity Therapeutics Inc

Evaluating the bottom line, Allarity Therapeutics Inc maintains a gross margin of 100.00%. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at -21436.00%, while the net margin is -24620.00%. These profitability ratios, combined with a Return on Equity (ROE) of -157.09%, provide a clear picture of how effectively ALLR converts its operational activities into shareholder value.

In the context of the broader market, ALLR competes directly with industry leaders such as DARE and BFRI. With a market capitalization of $15.31M, it holds a leading position in the sector. When comparing efficiency, ALLR's gross margin of 100.00% stands against DARE's -70.57% and BFRI's 79.92%. Such benchmarking helps identify whether Allarity Therapeutics Inc is trading at a premium or discount relative to its financial performance.

Allarity Therapeutics has reported zero revenue for the first three quarters of 2025, with a projected revenue of $320,000 in Q4 2025. The gross margin is expected to be 100% in Q4 2025, indicating potential profitability in the future if revenue can be sustained.